目的 探讨肾炎康复片联合恩格列净片治疗糖尿病肾病的临床效果。方法 选取2022年7月—2023年11月天津市天津医院门诊收治的70例糖尿病肾病患者，用随机表法将患者分为对照组和治疗组，各35例。对照组空腹口服恩格列净片，10 mg/次，1 次/d。治疗组在对照组的基础上口服肾炎康复片，5片/次，3次/d。两组连续治疗12周。比较两组的临床疗效、糖代谢指标、肾功能指标和血清炎症指标。结果 治疗后，对照组总有效率为71.42%，治疗组的总有效率为88.57%，组间比较差异有统计学意义（P＜0.05）。治疗后，两组的空腹血糖（FPG）、糖化血红蛋白（HbA1c）均显著降低（P＜0.05），治疗后，两组FPG、HbA1c组间比较差异无统计学意义。治疗后，两组尿素氮（BUN）、血肌酐（Scr）、尿微量白蛋白/肌酐比值（UACR）均较前下降（P＜0.05），治疗组BUN、Scr、UACR比对照组更低（P＜0.05）。治疗后，两组血清转化生长因子（TGF）-β1、肿瘤坏死因子（TNF）-α水平均较前下降（P＜0.05），治疗组患者血清TGF-β1、TNF-α水平比对照组更低（P＜0.05）。结论 肾炎康复片联合恩格列净片治疗糖尿病肾病提高了临床疗效，可改善其血糖水平，发挥肾脏保护作用，减轻患者的炎症反应。

Objective To explore the clinical effect of Shenyan Kangfu Tablets combined with Empagliflozin Tablets in treatment of diabetic nephropathy. Methods Patients (70 cases) with diabetic nephropathy admitted to the outpatient department of Tianjin Hospital from July 2022 to November 2023 were selected and divided into control group and treatment group by random table method, with 35 cases in each group. Patients in control group were po Empagliflozin Tablets on an empty stomach, 10 mg/time, once daily. Patients in the treatment group were po Shenyan Kangfu Tablets on the basis of control group, 5 tablets/time, 3 times daily. Both groups were treated for 12 weeks. The clinical efficacy, glucose metabolism index, renal function index, and serum inflammation index were compared between two groups. Results After treatment, the total effective rates of the control group and the treatment group were 71.42% and 88.57%, and the difference between two groups was statistically significant (P < 0.05). After treatment, FPG and HbA1c in two groups were significantly decreased (P < 0.05), and there was no significant difference in FPG and HbA1c between two groups. After treatment, BUN, Scr, and UACR in two groups were lower than before (P < 0.05), and BUN, Scr, and UACR in the treatment group were lower than those in the control group (P < 0.05). After treatment, the serum levels of TGF-β1 and TNF-α were decreased in two groups (P < 0.05), and the serum levels of TGF-β1 and TNF-α in the treatment group were lower than those in the control group (P < 0.05). Conclusion Shenyan Kangfu Tablets combined with Empagliflozin Tablets in treatment of diabetic nephropathy can improve the clinical effect, improve the level of blood sugar, protect kidney, and reduce the inflammatory response.

R983